488 related articles for article (PubMed ID: 8453790)
1. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
Ioannides CG; Whiteside TL
Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
3. Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope.
Quaratino S; Feldmann M; Dayan CM; Acuto O; Londei M
J Exp Med; 1996 Feb; 183(2):349-58. PubMed ID: 8627148
[TBL] [Abstract][Full Text] [Related]
4. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
5. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma.
Shimizu Y; Weidmann E; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Res; 1991 Nov; 51(22):6153-62. PubMed ID: 1718596
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
8. To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.
Thaxton JE; Li Z
Hum Vaccin Immunother; 2014; 10(11):3313-21. PubMed ID: 25483644
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. I. T cell receptor peptide regulation of T cell clones expressing cross-reactive V beta genes.
Offner H; Vainiene M; Gold DP; Celnik B; Wang R; Hashim GA; Vandenbark AA
J Immunol; 1992 Mar; 148(6):1706-11. PubMed ID: 1371785
[TBL] [Abstract][Full Text] [Related]
10. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
11. Cellular immunotherapy of cancer.
Yang JC
Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
[TBL] [Abstract][Full Text] [Related]
12. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides.
Chou YK; Morrison WJ; Weinberg AD; Dedrick R; Whitham R; Bourdette DN; Hashim G; Offner H; Vandenbark AA
J Immunol; 1994 Mar; 152(5):2520-9. PubMed ID: 7510747
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
Melief CJ; Kast WM
Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
[TBL] [Abstract][Full Text] [Related]
14. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
[TBL] [Abstract][Full Text] [Related]
15. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma.
Weidmann E; Elder EM; Trucco M; Lotze MT; Whiteside TL
Int J Cancer; 1993 May; 54(3):383-90. PubMed ID: 8509212
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
17. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
18. Human tumor antigens for cancer vaccine development.
Wang RF; Rosenberg SA
Immunol Rev; 1999 Aug; 170():85-100. PubMed ID: 10566144
[TBL] [Abstract][Full Text] [Related]
19. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
[TBL] [Abstract][Full Text] [Related]
20. Preferential usage of T cell antigen receptor V region gene segment V beta 5.1 by Borrelia burgdorferi antigen-reactive T cell clones isolated from a patient with Lyme disease.
Lahesmaa R; Shanafelt MC; Allsup A; Soderberg C; Anzola J; Freitas V; Turck C; Steinman L; Peltz G
J Immunol; 1993 May; 150(9):4125-35. PubMed ID: 7682589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
